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Se non puoi essere il sole, sii una stella 
Sii sempre il meglio di cio’ che sei. 
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Introduction 
 
1. Chronic Rhinosinusities  
 
Rhinosinusitis is a significant health problem which seems to 
mirror the increasing frequency of allergic rhinitis and which 
results in a large financial burden on society (1–3). The clinical 
presentation of CRS in individual patients covers a spectrum of 
severity, and CRS is probably best considered as a syndrome 
with persistent characteristic symptoms rather than a discrete 
disease entity. Until recently, research has been hampered by 
many factors, including most prominently the lack of a 
universally accepted definition.  
 
 
 
1.1 Definition and Diagnosis of rhinosinusitis/nasal polyps 
 
Rhinitis and sinusitis usually coexist and are concurrent in 
most individuals; thus, the correct terminology is now 
rhinosinusitis. 
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Because rhinitis and sinusitis are so closely linked the 
definition of CRS/NP in the EPOS document is developed 
from the ARIA classification of rhinitis and based on 
symptomatology, duration and severity of disease. 
The diagnosis of rhinosinusitis is made by a wide variety of 
practitioners, including allergologists, otolaryngologists, 
pulmonologists, primary care physicians and many others.  
Recently, the definition of rhinosinusitis has been revisedas an 
inflammation of the nose and the paranasal sinuses 
characterized by two or more symptoms (blockage, discharge, 
facial pain, reduction of smell) and either endoscopic signs 
(polyps, discharge from middle meatus, oedema/mucosal 
obstruction in the middle meatus) and/or CT changes within 
ostio meatal complex and/or sinuses (4,5). The presence of 
nasal polyps distinguishes two subgroups: CRS with or without 
polyps. 
 
1.2  Severity of disease 
The disease can be divided into MILD and 
MODERATE/SEVERE based on total visual analogue scale 
(VAS) score (0–10 cm): MILD ¼ VAS 0–4, 
MODERATE/SEVERE ¼ VAS 5-10. 
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Duration of disease. The disease can be divided into 
Acute/Intermittent (<12 weeks with complete resolution of 
symptoms) and Chronic/Persistent (>12 weeks symptoms with 
no complete resolution of symptoms). 
 
 
1.3 Rhinosinusitis and Allergy 
 
Acute rhinosinusitis. Review articles on sinusitis have 
suggested that atopy predisposes to rhinosinusitis (6). This 
theory is attractive given the popularity of the concept that 
disease in the ostiomeatal area contributes to sinus disease in 
that the mucosa in an individual with allergic rhinitis might be 
expected to be swollen and more liable to obstruct sinus ostia, 
reduce ventilation, lead to mucus retention that might be more 
prone to become infected. Furthermore there has been an 
increase in the body of opinion that regard the mucosa of the 
nasal airway as being in a continuum with the paranasal sinuses 
and hence the term rhinosinusitis (7). The number of studies 
determining the occurrence of acute rhinosinusitis in patients 
with and without allergy is very limited. 
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Chronic rhinosinusitis. It has been postulated (8) that swelling 
of the nasal mucosa in allergic rhinitis at the site of the sinus 
ostia may compromise ventilation and even obstruct sinus 
ostia, leading to mucus retention and infection. Furthermore, 
there has been an increase in the body of opinion that regard 
the mucosa of the nasal airway as being in a continuum with 
the paranasal sinuses and hence the term _rhinosinusitis_ was 
introduced (7). 
However, critical analysis of the papers linking atopy as a risk 
factor to infective rhinosinusitis (chronic or acute) reveal that 
whilst many of the studies suggest a higher prevalence of 
allergy in patients presenting with symptoms consistent with 
sinusitis than would be expected in the general population, 
there may well have been a significant selection process, 
because the doctors involved often had an interest in allergy (9-
14). A number of studies report that markers of atopy are more 
prevalent in populations with chronic rhinosinusitis. Benninger 
reported that 54% of outpatients with chronic rhinosinusitis had 
positive skin prick tests (15). Among CRS patients undergoing 
sinus surgery, the prevalence of positive skin prick tests ranges 
from 50 to 84% (16, 17, 18), of which the majority (60%) have 
multiple sensitivities (18). As far back as 1975, Friedman 
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reported an incidence of atopy in 94% of patients undergoing 
sphenoethmoidectomies (19). 
However, the role of allergy in CRS is questioned by other 
epidemiologic studies showing no increase in the incidence of 
infectious rhinosinusitis during the pollen season in pollen-
sensitized patients (20). In a small prospective study, no 
difference in prevalence of purulent rhinosinusitis was found 
between patients with and without allergic rhinitis (21). 
Newman et al. reported that whilst 39% of patients with CRS 
had asthma, raised specific IgE or an eosinophilia, only 25% 
had true markers to show they were atopic (22). Finally, 
Emanuel et al. (18) found relatively lower percentages of 
allergic patients in the group of patients with the most severe 
sinus disease on CT scan and Iwens et al. (23) reported that the 
prevalence and extent of sinus mucosa involvement on CT was 
not determined by the atopic state. 
Not with standing the lack of hard epidemiologic evidence for 
a clear causal relationship between allergy and CRS, it is clear 
that failure to address allergy as a contributing factor to CRS 
diminishes the probability of success of a surgical intervention 
(24). 
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1.4  Lower airway involvement in CRS 
 
Recent evidence suggests that allergic inflammation in the 
upper and lower airways coexist and should be seen as a 
continuum of inflammation, with inflammation in one part of 
the airway influencing its counterpart at a distance. 
Rhinosinusitis and lower airway involvement are also 
frequently associated in the same patients, but their 
interrelationship is poorly understood. 
 
2. Tissue remodeling in upper airways 
 
Several years ago, Bousquet et al. proposed as definition of 
remodelling : model again or differently, reconstruct_ 
following the Oxford Dictionary (25). 
Remodelling is a critical aspect of wound repair in all organs 
representing a dynamic process which associates matrix 
production and degradation in reaction to an inflammatory 
insult leading to a normal reconstruction process (model again) 
or a pathological one (model differently). However, it also 
appears that some components of remodelling are 
constitutional and may be genetically driven (26). 
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Finally, this definition stresses the close relationship between 
the initial inflammation and the subsequent tissue damage. 
 
2.1 Remodelling in the nose 
 
Remodelling in the nose is more complex. In allergic rhinitis, 
nasal remodelling may exist, but, even if the links between 
rhinitis and asthma are evident (27, 28), it is far less extensive 
than in the bronchi of asthmatics. These differences between 
upper and lower airways could be considered as a consequence 
of different embryologic origin (29). 
After trauma or surgery in airways, a scar may be observed as a 
pathological consequence of abnormal remodelling. Finally, 
there are other nasal or paranasal sinus conditions presenting 
some degrees of remodeling which can significantly interfere 
with the normal functions of the respiratory mucosa. 
 
 
2.2  Normal nasal and paranasal mucosa 
 
The nasal mucosa is the first physical barrier to foreign 
materials and a conditioner for inhaled air. The nose and, also 
probably the paranasal sinuses, also assume largely other 
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functions mainly necessary for conditioning the inspired 
airflow (30). The nasal epithelium is separated from the lamina 
propria by a continuous basement membrane (Fig. 1A). The 
pseudostratified columnar epithelium (respiratory epithelium) 
is composed of four major types of cells: ciliated, non ciliated, 
goblet and basal cells. A functional nasal mucosa can assure 
mucus production and transport, resorption of surface 
materials, and formation of new epithelial cells. The proportion 
of goblet cells was higher in inferior turbinate and lower in the 
nasal septum (31). Just beneath the basement membrane, 
lymphocytes and plasma cells forms  the lymphoid layer of the 
lamina propria. The supporting connective tissue is of loose 
type and its extracellular matrix (ECM) component plays an 
essential role in inflammatory reactions. The subepithelial 
region also contains two layers of sero-mucous glands: the 
superficial layer is situated just underneath the epithelium, and 
the deep layer under the vascular layer. 
Besides resistant vessels, such as arteries, arterioles or 
capillaries, the vasculature of the nose is characterized by 
capacitance vessels, designated as _erectile tissue_. This 
vascular component is mainly concentrated on the middle and 
inferior turbinates, the septum and may extend posteriorly to 
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the choanal orifices. With these vascular specificities, the nasal 
mucosa can regulate the airflow, adapt the nasal resistance, 
filter and condition the inspired air by producing nasal mucus, 
sustaining a mucociliary transport and serving as support for 
immune response. 
The mucosa isolated from maxillary sinuses is slightly 
different, mainly thinner and less specialized than nasal 
mucosa (Fig. 1B). The respiratory epithelium is lower and 
contains less goblet cells (32). The epithelium contains fewer 
cilia than the nasal mucosa (33). The basal lamina is always 
easily identifiable. The glands are fewer and smaller and the 
venous erectile plexus is absent (34). 
The differences in mucosal structures could be explained by 
differences in flow of inspired air (35) or in extent of 
mesodermisation during the formation of the mid-face and 
nasal cavities from in utero weeks 4–12. It is probable that 
other hypotheses will appear when the intrinsic functions of the 
paranasal sinuses can be better defined. 
The inflammation occurring in this region is frequent and many 
pathological processes could induce chronic types of 
inflammation. These situations lead regularly to structural 
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changes in epithelium or lamina propria, but the precise 
relation remains unclear (36). 
 
 
 
 
 
 
 
 2.3 Tissue Remodelling in Chronic rhinosinusitis with or 
without nasal polyps 
 
In humans, tissue remodelling in the upper airways cannot be 
restricted to the very limited tissue damage occurring during 
allergic rhinitis. Depending on the initial induction 
(inflammation, trauma), the upper airways can present different 
types of remodelling: allergic inflammation in allergic rhinitis, 
Figure.1 Histomorphological view of normal (A) 
nasal and (B) paranasal mucosa (Ep: epithelial cells; 
Bm: basement membrane; L1: lymphoid layer; Gl: 
glands; BV: blood vessels; CT: connective tissue). 
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persistent oedema and in chronic rhinosinusitis (CRS) with 
nasal polyps, purely fibrotic tissue like nasal adhesions, or 
mixed oedema and fibrosis as CRS without nasal polyps. 
 
Chronic rhinosinusitis without nasal polyps. The mucosallininn  
CRS without polyp is characterized by basement membrane 
thickening (37), goblet cell hyperplasia, limited subepithelial 
oedema, prominent fibrosis and mononuclear cell infiltration 
(38 Fig. 2A, B). Interestingly, the fibrosis is usually limited to 
collagen deposition mostly in subepithelial regions. In this 
disease, the MMP and TIMP ratio seems to be balanced (39). 
 
 
Chronic rhinosinusitis with nasal polyps. In contrast to CRS 
without nasal polyps, CRS with polyps reveals frequent 
epithelial damage, a thickened basement membrane and mostly 
oedematous to sometimes fibrotic stromal tissue, with a 
reduced number of vessels and glands but virtually no neuronal 
structure (38; Fig. 2C,D). Recent hypotheses suggested that 
mammaglobulin may contribute to epithelial proliferation in 
polyp formation (40).  
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Figure 2. Major types of extracellular matrix remodeling in 
paranasal diseases. Schemes illustrating the major changes in 
lamina propria (left column) and corresponding pathological 
views (right column). (A) Chronic rhinosinusitis without 
polyps: transforming growth factor-β1 staining (initial 
magnification x100). (C) Chronic rhinosinusitis with polyps: 
severe subeithelial inflammation (IR) and massive oedema (OE) 
in lamina propria with fields of fibrotic foci (F). (D) Chronic 
rhinosinusitis with polyps: EG2 staining for eosinophils (initial 
magnification x100) 
 
 
19 
 
Polyps demonstrate increased exudation from vessels, oedema 
of the lamina propria and bulging of the nasal mucosa (Fig.3).  
Nasal polyps have been histologically classified into 
oedematous, glandular and fibrous types (41) according to their 
stroma remodelling. Among the inflammatory cells, EG2+ 
(activated) eosinophils, usually located around vessels and 
glands, are a prominent characteristic in about  80% of patients 
with nasal polyps. 
 
 
 
 
 
Figure 3: Typical appearance  of nasal  polyposis 
in right middle meatus. 
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The oedematous nature of nasal polyps consists of fibroblasts 
and infiltrating inflammatory cells localized around pseudocyst 
formations. These pseudocysts contain albumin and other 
plasma proteins, this active exudation being supported by the 
subepithelial eosinophilic inflammation. 
 Finally, increased aquaporin-1 water channel expression in 
polyp tissue could influence oedema formation (42). Mostly, in 
CRS with polyps and aspirin sensitivity, epithelial thickening 
and eosinophilia was found in inferior turbinates at distance 
from the polyps (43).  
Recently, an imbalance between MMPs and their natural 
inhibitor TIMP-1 has been reported in CRS with nasal polyps. 
This imbalance could lead to a local increase of ECM 
degradation and formation of pseudocysts (44). 
 Like neutrophils and macrophages, mast cells can express 
MMPs and interact with ECM (45). This view was recently 
supported by evidence of participation of other MMPs, such as 
MMP-2 (46–48)  in pathogenesis of CRS with nasal polyps. 
Finally, this clinical entity must be distinguished from the antro 
choanal polyp, which presents microscopic similarities with 
maxillary cyst (49). 
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2.4 Histology of nasal polyps 
 
Some theories consider polyps a consequence of conditions 
which cause chronic inflammation in the nose and nasal 
sinuses characterized by stromal edema and variable cellular 
infiltrate (50). They consist of loose connective tissue, edema, 
inflammatory cells, and some capillaries and glands. They are 
covered with different types of epithelium, most commonly 
pseudostratified respiratory epithelium with goblet cells and 
ciliated cells. It presents thickening of the basement membrane, 
a loose of a vascular edematous stroma and an infiltrate of 
plasma cells and eosinophils. Eosino  phils are found in 85% of 
NP with the remaining cells being predominantly neutrophils 
(51) (Fig.4).  
 
 
Figure 4: Typical histological apparence of nasal 
polyposis. Ematossiline/eosine staining for subepithelial 
inflammatory cells (initial magnification x40). 
ubepithelial eosinophilic inflammation 
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3. Interleukin-19: Multiple roles in immune regulation and 
disease 
3.1 Introduction 
Despite being first published in 2000, no clear role for 
interleukin-19 has yet been defined. Scientific interest in it is 
high, but actual hard information is thin on the ground for a 
cytokine discovered over 10 years ago, indeed, IL-19 has the 
dubious distinction of being a cytokine which has appeared in 
almost more review articles than in primary scientific 
investigations (e.g. 52).  
IL-19 is a member of the IL-10 family of cytokines, forming a 
subfamily with IL-20 and IL-24, and more broadly with the 
Type-I, -II and -III interferons (Fig. 5). The earliest member of 
the IL-19/20/24 subfamily, and the only one with a known viral 
paralog, is IL-24 (53). Like the members of the IFN-l family 
(54), IL-10 family members‘structures are conserved  tightly 
between species. The gene encoding IL-19 comprises seven  
exons and is located on human chromosome 1.  
Secreted IL-19 is composed of 159 amino acids that form an a-
helical structured protein. IL-19 is produced by activated 
monocytes, and to a lesser extent, by B-cells (55), but also by 
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non-immune cells such as keratinocytes and foetal membranes 
(56). As known so far, IL-19 functions through a receptor 
complex composed of IL-20Ra and IL-20Rb that is also 
utilized by IL-20 and IL-24. High levels of both receptor 
chains are present in several tissues including the skin, lungs 
and tissues from the reproductive organs, but the alpha chain 
appears to be absent from immune cell populations. 
Nonetheless, many effects of the IL-19 described to date 
concern immune cells. IL-19 has been shown to enhance the 
production of Th2 cytokines in T cells and to be elevated in 
asthma patients. Furthermore, it induced IL-6, IL-8 and IL-10 
expression in monocytes. Additionally, it has been implicated 
in a range of diseases and disorders, including (but not limited 
to): aging (57), Type-I diabetes (58), endotoxic shock (59), 
periodontal disease (60), vascular disease (61) and rheumatoid 
arthritis (62,63) These sporadic encounters between IL-19 and 
human disease stand as testimony to there being no clearly 
defined role for this cytokine in human biology (other than the 
potential role in atopic and allergic responses and disorders; 
see below). It also seems to be involved in the pathogenesis of 
the Th1-type skin disease psoriasis, where both ligand and 
receptor are present. IL-19 therefore represents a cytokine with 
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apparently contradictory functions and whose receptor is not 
always apparent on its target cells; its immunoregulatory 
functions are far from determined.  
 
 
 
 
 
 
 
 
Figure 5: Evolutionary relationship of members of the IL-
107IFN clan. Evolutionary relationships between IL-19 and 
the other subfamily members (shared red), the IL-10 
subfamily (blue), the Type –III (lambda) IFNα members 
(orange) and the other Type –II IFNs (pink) are shown. 
Relationships are based on protein sequence, excluding 
putative leader sequences. 
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3.2 The human IL-19 protein, receptor and signaling 
 
 
  
IL-19 is a member of the IL-10 family of cytokines (52, 64). In 
original analysis of IL-19 (64), was described 30 identical 
amino acids, including those analogous to the four cysteine 
residues necessary to correctly fold the α-helices in the IL-10 
protein. In addition, a further 36 were similar. Strikingly, 41 of 
the 50 amino acids previously identified  as being essential to 
the hydrophobic core of IL-10 were conserved in IL-19.  
The subsequent crystallization of IL-19 has revealed a very 
similar structure to that of IL-10, except that IL-19 has seven 
helices rather than six and is capable of folding back on to 
itself to forma stable monomer in solution.  
The ‗‗IL-10 family F-helix motif‘‘ (K.x.x.x.E.x.D), found in all 
human IL-10 family members, is located on the IL-19 G-helix, 
as ‗‗K.S.L.G.E.L.D‘‘. Unlike IL-10, IL-19 is not a homodimer 
in solution; it forms a stable, functional monomer. 
Structurally, IL-19 is a smooth, compact seven a-helical 
structure (A–G), held together by two disulphide bonds 
(Cys57–Cys109 andCys58–Cys111) that parallel those found 
in IL-10, and an extensively hydrophobic core (65) (Fig.6). 
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IL-19 mRNA expression was first demonstrated in primary 
human monocytes following stimulation with LPS or 
granulocyte–macrophages colony stimulating factor; other 
cytokines (IFN-g, IL-10, IL-4 or IL-13) could not them selves 
stimulate IL-19 transcription (64). The data also showed that 
Figure 6 Crystallization of IL-19. IL-19 is a 
smooth, compact seven a-helical structure(A–G), 
held together by two disulphide bonds (Cys57–
Cys109 andCys58–Cys111) that parallel those 
found in IL-10, and an extensively hydrophobic 
core. 
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LPS  induction of IL-19 was enhanced by IL-4 but not by IFN-
g. It was also demonstrated that IL-19, in common with many 
monocyte-derived cytokines, is subject to feedback inhibition 
by IL-10 (66); stimulation of IL-19 secretion with LPS could 
be inhibited by the addition of IL-10 to the culture. 
In complementary experiments, addition of monoclonal anti-
IL-10 antibody to the cultures caused an increase in IL19  
transcription, indicating that even endogenous IL-10 exerted 
measurable control over IL-19 production. 
IL-19 is similar in sequence and structure to IL-10, but much 
more so to IL-20 and IL-24 (67), and we have described these 
three cytokines as the ‗‗IL-19 subfamily‘‘. While others prefer 
‗‗IL-20 subfamily‘‘ (68), their evolutionary relationship 
suggests that the honour should in fact fall to IL-24. An 
additional element of similarity comes from their sharing a 
common element to their receptor—the IL-20Rb chain (69). 
IL-19, IL-20 and IL-24 can all bind to a hetero dimeric receptor 
complex comprising the IL-20Ra and IL-20Rb chains, and 
signal thephosphorylation of STAT3 efficiently.  
Rather, IL-19 may well utilize some alternative receptor on 
lymphoid cells. Of interest in this regard is the observation that 
it is the IL-20Rb chain and not the Ra chain, that binds IL-19 
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with high affinity (stable 20Ra:IL-19:20Rb complexes) are 
only formed after IL-19 binds 20Rb (70). 
Early reports addressing IL-19-induced signaling demonstrated 
clearly that the main pathway is the tyrosine phosphorylation 
(69,71) and nuclear translocation (71) of STAT3. Both reports 
utilized cells transfected with various combinations of receptor 
chains. Moreover, these authors showed that, while STAT1 
was also activated, this required a 100-fold greater ligand 
concentration. 
They also showed that IL-20 effects required 10-fold less IL-20 
when mediated via the ‗‗alternative‘‘ IL-20 receptor 
(IL22Ra/IL-20Rb) than that of either IL-19 or IL-20 when 
using  the ‗‗original‘‘receptor pair (71). In a more recent study 
using the HaCaT human keratinocyte cell-line, IL-19-induced 
STAT3 tyrosine phosphorylation was clearly detected, 
although at lower levels than that induced by IL-20 and IL-24 
(72). Interestingly, the ability of IL-19 to inhibit the growth of 
the OvCar-3 cell line (which expresses the20R1/2 heterodimer) 
is accomplished in the absence of STAT3 or STAT1 
phosphorylation or translocation, suggesting some alternative 
signaling mechanism may be triggered by IL-19 binding to 
these cells (71). 
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3.3 IL-19 and inflammatory disorders 
Two interesting studies have addressed the subject of vascular 
disease. In the first, Tian et al. (73) describe the induction of 
IL-19 in human vascular (arterial) smooth muscle. Proliferation 
of these cells was markedly inhibited by IL-19 in vitro and this 
was accompanied by SOCS5 induction (74). Adenoviral 
administration of  IL-19 to rats effectively reduced injury, and 
MAP kinase activation. More recently, inflammatory cytokines 
were shown to induce IL-19 in these same cells (61), while 
administration of IL-19 reduced the inflammatory response in 
vascular smooth muscle by diminishing the stability of mRNA 
species encoding proinflammatory proteins. 
This work correlates well within patients suffering from septic 
shock (59). These patients display elevated IL-19 peripheral 
titres and human lung and liver cells were activated to undergo 
apoptosis or release reactive oxygen species by IL-19, in vitro. 
In addition, significant activation of neutrophils was observed. 
In LPS challenged mice, administration of soluble IL-19 
receptor reduced these pro-inflammatory indices of IL-19‘s 
activity. Conversely, ininflammatory bowel disease, 
endogenous IL-19 appears to be protective. Azuma et al. (75) 
examined the DSS colitis model in IL-19_/_ mice and showed 
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that these mice were more susceptible to colitis than their 
immunologically intact cousins. Here, it was macrophages and 
their associated pro-inflammatory TNF, IL-1 andIL-6 whose 
accumulation was enhanced in the absence of IL-19 (these 
cytokines were also enhanced following LPS stimulation in 
vitro).  
 
 
3.4  IL-19, the Th2 response and asthma 
The majority of the data implicate IL-19 as a component of the 
Th2 system and clinically, as having a clear role in asthma. 
In an original description of IL-19 (64), was noted that IL-19 
expression in LPS-stimulated monocytes was enhanced by 
preincubation of the monocytes with IL-4 and, to a lesser 
extent, with IL-13. These data were strengthened by 
experiments on human T-cells, where the presence of IL-19 
elevated the proportion of IL-4+ve CD4+ve T-cells, to the 
detriment of the numbers of those that were IFN-g positive 
(76). A corresponding up regulation of IL-4 mRNA was also 
observed (67). These observations were recently confirmed and 
extended by Oral et al. (77), who demonstrated that repeated 
rounds of stimulation of naive human T-cells in the presence of 
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IL-19 polarised these cells to a Th2 secretory (elevated IL-4, 
IL-13 and diminished IFN-g) phenotype. Evidence for direct 
effects on human B-cells, leading to elevated IgG levels has 
also been presented (78). 
The induction of Th2 cytokine expression by IL-19 has also 
been confirmed for the murine system (79). Using activated 
splenic CD4+ve T-cells, this group demonstrated that 
introduction of IL-19 caused increased secretion of IL-4, IL-5, 
IL-10 and IL-13, confirming and extending the available 
human data. In addition, these effects could  be manifest in 
vivo. Introduction of an IL-19-encoding plasmid DNA to 
immunologically intact mice caused an elevation of serum 
levels of IL-4, IL-5 and IL-10 (79). It therefore appears that 
one of the main physiological functions of IL-19 is to 
participate in the promotion of the Th2 response and in final 
proof of this is required, there cent cloning and expression of 
avian IL-19, and the demonstration that it to oup regulates Th2 
responses, should suffice (80). 
Dysregulated Th2 responses are associated with certain 
diseases. Some of these, such as uremia, are acute and 
transient. 
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Nonetheless, elevated Th2 responses in uraemic patients are 
accompanied by elevated IL-19 titres (81), and IL-19 is present 
with other Th2 cytokines in uveitis (82). However, the best-
known Th2 disease in man is asthma. 
Asthma is a chronic condition characterized by increased 
bronchial responsiveness and by airway obstruction and 
inflammation; it is a significant, and growing, problem in the 
Western World interms o morbidity and economic impact. 
According to the NHLBI, 15million adults and children have 
asthma in the USA (one case per300people), causing around 
0.5 million hospital admissions annually, over 5000 deaths, and 
over 15% of all paediatric emergencies (83). 
Current treatments only relieve the symptoms, failing to 
address the underlying immunological mechanisms. Its 
economic impact has been estimated at over $16B per year. 
The incidence is highest in children (‘75 cases per thousand); 
numbers have been rising over the last 20 years. Although 
asthma development is multifactorial, Th2 cytokines are highly 
associated with the disease, especially IL-4, IL-5 and IL-13, 
which are secreted following antigen challenge in allergic 
asthma (84-86). Experimentally, IL-19 mRNA levels were 
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elevated in the lungs of BALB/c mice, following exposure to 
allergen; the mice also had elevated serum IL-19 (84). 
In human patients, Liao et al. (79) demonstrated that IL-19 
levels were elevated 3–4-fold in the serum of children with 
asthma, over normal children or adults. High IL-19 levels 
correlated with high IL-4 and IL-13 levels. Huang et al. (91) 
expanded these results by demonstrating that epithelial cells in 
theair way of human asthma and COPD (chronic obstructive 
pulmonary disorder) patients were rich in IL-19. Further, as 
described above, bronchial epithelial cells in this study 
responded to synergistic stimuli by IL-17 and IL-13 (both key 
asthma mediators (87,88) to express IL-19 at high levels, 
demonstrating positive feedback between the Th2 and pro-
inflammatory aspects of asthma, and increased IL-19 
expression. 
Interestingly, it has also been shown that stimulation of 
adenosine receptors on human bronchial epithelial cells would 
induce IL-19 secretion. This could induce TNF secretion from 
THP-1cells which in turn would elevate the A2B adenosine 
receptor on the bronchial cells (89), increasing adrenergic 
responsiveness and elevating the cycle of both inflammation 
(via TNF) and Th2 responses (via IL-19). The responsiveness 
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of IL-19 expression to adrenergic stimulation was recently 
independently confirmed (90). 
Thus, IL-19 is very closely associated with the Th2 response, 
and with human asthma, with important contributions from 
Th17 cells (91). IL-13 is key to driving many of the asthma 
symptoms (92-94). 
Thus there may be a cycle of IL-19 up regulating Th2 and 
inflammatory cytokines, which in turn up regulate IL-19. How 
this cycle contributes to pulmonary host defense and/or asthma 
susceptibility and progression, remains to be determined 
(Fig.9). 
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Figure 9. IL-19 drives pathogenic Th2 and inflammatory mechanisms in asthma. As 
discussed in the text, airway epithelial cells secrete IL-19, and this is stimulated 
synergistically by IL-17 and IL-13 [39]. IL-19 promotes the development and function 
of Th2 cells [82]. In addition, monocytes are IL-19 responsive, secreting TNF which 
also promoted IL-19 secretion from airway epithelial cells [94,95]. Thus ,in the airway, 
IL-19 may lie at the pivot point of the two key pathogenic pathways that combine to 
produce asthma in man: the Th2 response and the inflammatory response. Th2, 
CD4+ve T-helper Type-II cells; Th17, CD4+ T-helper, IL-17 secretor cells. 
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AIMS 
 
Chronic rhinosinusitis (CRS) is an inflammatory disease of the 
nasal and paranasal sinus mucosa. Patients with CRS are 
symptomatic for longer than 3 months and have associated to 
inflammatory mucosal thickening and sometimes to polyploid 
changes. 
An improved understanding of mechanisms that lead to the 
formation of nasal polyps in allergic or non allergic patients 
affects with Chronic Rhinosinusitis, may foster the 
development of more effective therapies.  
Thus, the aims of the present study are: 
 To demonstrate whether a specific biomarker promote 
tissue remodeling  in Chronic Rhinosinusitis.  
 To asses the contribute of allergy in these phenomena. 
 
Current methods of research in CRS/NP select and probe for 
known inflammatory cytokines and chemokines and their 
corresponding  mRNA transcript. 
In designing our study, we looked to recent research strategies 
with potential applicability to nasal polyps and nasal mucosa. 
Because it has been assumed that  nasal polyps from patients 
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affected by CRS, should share a common cytokine milieu with 
asthma, sinusitis, or allergic rhinitis, we used Human Asthma 
Gene Array to study the phenomena. 
Gene expression arrays are powerful new tools that can provide 
important information about the identification of inflammatory 
molecules which may lead to the identification of specific 
genes and signaling pathways involved in airway remodeling 
and inflammation that occour in Chronic Rhinosinusitis 
disease. 
In this study, we‘ll use a real-time PCR approaches to confirm  
gene expression, instead we‘ll use western blot and  
immunohistochemistry to evaluate protein expression  and its 
localization at level of specific cells types. 
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RESULTS 
 
We studied 30 patients. Characteristics of patients are shown in 
Table 1. Two groups were formed according to the presence of 
Chronic Rhinosinusitis (CRS). Group 1: patients undergoing 
surgery for non-CRS pathological conditions (control group) in 
which CRS, nasal polyps  and allergy  were excluded based on 
clinical and radiographic analysis (n = 10), Group 2: patients 
with CRS, without nasal polyps, (with or without allergy) 
(CRSw/oNPt) (n = 10). Group 3: Nasal polyposis, also 
referred to as (CRSwNPt), present on CT scan and/or 
endoscopic examination from CRS patients (with or without 
allergy) (n=10).  
Patients smokers, with an established immunodeficiency, a 
diagnosis of classic allergic fungal sinusitis, or cystic fibrosis 
were, however, excluded from the study. Patients with allergy 
were distinguished from those without allergy on the basis of 
allergy skin tests. 
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Biomarker’s  identification in CRS patients with nasal polyps: 
Gene Expression Analysis 
 
Because it has been previously demonstrated that in patients 
with chronic inflammatory airway diseases can contribute to 
the pathogenesis of rhinitis, nasal polyps, acute asthma, cystic 
fibrosis, and COPD (95-99) and that the remodeling of lower 
airways correlate with those of the upper airways (27, 28), it 
was first evaluated wether some specific biomarkers in nasal 
     Table 1. Characteristics of patients 
                                                                 Normal                            CRSw/oNPt                            CRSwNPt       
                                                               ( Group 1)                        (Group 2)                             (Group 3)        
    
  Patients (n)                                            10                                          10                                       10 
  Age (year) (mean)                         38.5 ± 9.8                              35.1±5.7                           57.6±16 
  Gender (male/female)                        5/5                                      5/5                                      5/5 
  Duration of disease years (mean)     0                                        8.6                                       7.2 
  Total IgE (KU/L) (mean)                        0                                       339                                      516 
  Incidence of elevated total IgE            0                                        50%                                    50% 
 (>128 KU/L)          
  Incidence of allergy†                             0%                                     45%                                   50% 
 
†Defined as a positive skin prick test to at least 1 allergen in a panel of 16 common aeroallergens 
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polyposis promote tissue remodelling  in Chronic 
Rhinosinusitis. 
Focus was placed on genes differentially expressed in the 
normal nasal mucosa and polyps of patients with CRS with or 
without allergy. During a pilot phase of this study, 20 CRS 
patients underwent biopsies, 10  were control subjects  and 10 
were CRS patients with nasal polyps (CRSwNP). 
However, only 5 of 10 sample produced RNA in sufficient 
quantities and quality to undergo analysis with gene array.  
This array was unfortunately discontinued by the manufacturer 
during the study. 
 Analysis of nasal polyp samples revealed a similar gene 
expression pattern between patients. Gene analysis revealed 
changes in expression of several key genes that code for 
chemokines, cytokines, receptors, and signal transduction 
molecules. The most significant changes in expression (>2.5 
fold) were noted for IL-19, after analysis with the Human 
Asthma Gene Array (Fig.10).  It was found to be expressed 5,3 
fold higher in the nasal polyps of the patients with CRS 
independently of allergy, compared with the control subjects 
(Fig.11). 
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Therefore, gene array analysis demonstrated, that receptor  for 
the costant fragment of immunoglobuline E (FCR1A) was 
upregulated, instead the expression level of Interferon alpha 1 
IFN-a 1 gene was decreased (see table2). 
 
                      PATIENT 1                                                   PATIENT 2 
                                CONTROL                                            CRS/NASAL POLYP 
         
 
        
IL-19 
Figure 10. Changes in gene expression in nasal polyps. Note the increase 
in expression of IL-19 gene in nasal polyps from patients with CRS/NP. 
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Figure 11. Representative analysis performed by the GEarray analyzer 
program showing the differences in gene expression between Control 
and CRS/NP groups. 
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Changes in expression  of IL-19 gene in patienst with different 
degrees of Chronic Rhinosinusitis 
 
To verify the reliability of findings from the gene array 
analysis, we analyzed mRNA samples from nasal mucosa and 
nasal polyps of 15 additional subjects (nasal mucosa from 5 
control subjects, nasal mucosa from 5 CRS patients and 5 nasal 
polyps from CRS patients, (CRS patients with or without 
allergy). 
Table 2 
Expression of up- or down-regulated genes. (changes in expression > 2.5 
fold) 
 
Gene Bank ID               Gene definition                Genesymbol 
NM 013371                 IL 10C7MDA                         IL-19 
NM002001                  Fc fragment of IgE                FCR1A 
NM024013                  Interferon alpha 1                 IFL/IFN 
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The quantitative gene expression of the IL-19 gene was 
determined by Real-time PCR and is displayed in Fig. 12. 
The IL-19 gene expresion was detectable in all samples, but 
high levels of expression of mRNA were detected in nasal 
polyps from CRS patients (see A, Fig.12).  
For to establish a role of allergy in CRS, we also evaluated, IL-
19 mRNA expression in 5 subgroups:  control group in which 
CRS, nasal polyps  and allergy were excluded (CON), patients 
without CRS, without nasal polyps and with allergy (CONwA), 
CRS patients without nasal polyps, with allergy (CRSwA) and 
without allergy (CRSw/oA), and nasal polyps from CRS 
patients with allergy (CRS/NPwA) and without allergy 
(CRS/NPw/oA).  
IL-19 gene expression was detectable in all samples, but high 
levels of expression of mRNA were detected in nasal polyps 
from CRS patients indipendently of allergy. Low levels was 
also detected in nasal mucosa of patients CRS with/without 
allergy (see B, Fig.12). 
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Figure.12: Real-Time confirmed the increased expression of IL-19 mRNA in CRS 
with Nasal Polyps. (A,B).GAPDH gene expression was used as endogenous control 
for normalization. Relative quantitation of mRNA was carried out with comparative 
CT method. 
 A                                        CAL                   CON               CRS/NPt 
 
    
 
             B                                        CAL        CON      CONwA   CRSw/oA   CRSwA   CRS/NP    CRS/NP 
                                                                                                                                                      wA         w/oA 
               
                           
46 
 
IL-19 proteine expression confirme mRNA levels 
 
Next, we measured the levels of IL-19 protein by 
immunoblotting after incubation with specific antibody. We 
observed that IL-19 protein were detectable in lower 
expression in control subjects, however, a robust increase  were 
detectable in CRS/NP (with or without allergy)  and in lower 
extent in CRS w/o NP (with or without allergy) (Fig. 14, A). In 
second step, to determine whether the allergy play a role in IL-
19 expression, we analyzed it in 5 differents subgroups : 
control (CON), CRS patients without allergy (CRSw/oA), CRS 
patients with allergy (CRSwA), CRS patients with NP and 
without allergy(CRS/NPw/oA), and CRS patients with NP and 
allergy( CRS/NPwA). We seen that there were not detactables 
change in expression between groups, infact we seen no 
differences between allergic CRS patients without NP with 
allergic and non allergic CRS patients with nasal polyps, 
therefore no difference were present between  nasal polyps 
from allergic and non allergic CRS patients (Fig.14, B).  
Those IL-19 seems to be specifically a nasal polips marker. 
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IL-19 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
Figure. 14. ± Detection of Interleukine 19 (IL-19) via Western immunoblots. The total protein (20 µg) 
extracted from nasal mucosas and nasal polyps from CON, CRS patients with or without nasal polyps, with or 
without allergy and NP from CRS patient with or without allergy, were run on the 12% polyacrilammide gel  
and a goat polyclonal antihuman IL-19 (Santa Cruz) used for detection. IL-19 was detected in its dimeric 25 
kDa form: intensely onNasal polyps and  moderately on nasal mucosas from respectly CRS patients with or 
without allergy. STD: molecular weight standards (kDa). 
 
 
   CON             CRSt       CRS/NP 
 
 
 
 
 Il-19 
25 KDa 
Beta actin 
45 Ka   
    CON       CRSw/oA        CRSwA      CRS/NP   CRS/NP 
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Localization of IL-19 protein in the upper airways 
 
In this initial study, we analyzed overall gene expression with 
RNA from the entire nasal mucosas and nasal polyps 
speciments. It is likely that some genes are expressed to a 
greater degree in the epithelium, whereas others are expressed 
more in the stroma. It is also likely that gene expression within 
eosinophils, lymphocytes, dendritic cells, and other cells may 
differ and hold clues to the specific pathophysiologic 
mechanisms at play. 
Therefore, to investigate the levels expression of IL-19 protein 
and the role in remodelling mechanisms, we observed the IL-
19 protein expression in metaplastic area of nasal polyps 
ephitelium. On  immunohistochemistry staining, the epithelium 
in CRS/NP sample demonstrated a mucosal hypertrophy, 
hyperplasia and metaplasia of epithelial goblet cells. A large 
number of inflammatory cells such as plasma cells, 
lymphocytes, macrophages and eosinophils was noted. 
Interestingly, it has been shown that the major cell type stained 
specifically positive for IL-19 were ephitelial cells (Fig.15). In 
according with a study, we established a staining IL-19 level 
score: low intensity (score 1-3) and high intensity (4-9).  We 
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evaluated IL-19 staining in normal, hiperplastic and 
metaplastic  ephitelium from nasal polyps of CRS patients and 
we observed that the intensity of staining was more evident in 
metaplastics area than hiperplastic and normal  ephitilium. 
More staining were the macrophages and glandular cells. (Data 
not shown). 
 
       
 
 
 
 
 
 
 
 
 
Figure 15. Immunohistochemical staining for Interleukine 19 (IL-19) in 
epithelial cells of human nasal polyp tissue and nasal mucosa at 400 x 
magnification. IL-19 immunoreactivity is weak  in hypertrophic 
ephitelium (A). Squamous metaplastic epithelium showed higher 
expression of IL-19 protein in CRS nasal polyps (B). 
                    
        A                                                             B 
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DISCUSSION 
 
Chronic rhinosinusitis (CRS) is an inflammatory disease with 
distinct cytokine and remodeling patterns. Chronic 
rhinosinusitis with nasal poyps (CRSwNP) is characterized by 
a Th2-skewed eosinophilic inflammation, whereas chronic 
rhinosinusitis without nasal polyps (CRS) represents a 
predominant Th1 milieu. However, although nasal chronic 
inflammation can lead to obstruction and subsequent chronic 
rhinosinusitis (95), not all individuals with chronic nasal 
inflammation develop CRS or CRSwNP visible on CT 
imaging.  
Previous studies showed the presence of IL-19 in the epithelial 
cells of the bronchus and small airways, but no data are 
available to date on IL-19 expression in the upper airways.  
In this study we found for the first time an increased expression 
of IL-19 in patients with chronic rhinosinusitis (CRS). The 
increase was high in patients with CRS with nasal polyps (NP), 
less in those without NPs. The increased expression of IL-19 
was mainly shown the squamous metaplastic epithelium of 
nasal polyps, not only in tissue infiltrating inflammatory cells 
(data not shown), which commonly represent the primary 
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source of IL-19. These data are consistent with what reported 
by other studies, showing an increase of IL-19 levels in 
different epithelia, such as bronchial epithelium under 
inflammatory conditions.  
It was also shown that inflammatory stimuli can induce IL-19 
in other non-immune cells such as keratinocytes and foetal 
membranes (56). IL-19 is produced by activated monocytes, 
and to a lesser extent, by B-cells (55),  
The majority of data implicate IL-19 as a component of the 
Th2 system and demonstrare a clear role in asthma. Although 
asthma development is multifactorial, Th2 cytokines are highly 
associated with the disease, especially IL-4, IL-5 and IL-13, 
wich are secreted following antigen challenge in allergic 
asthma (89-91). Il-19 mRNA levels were found elevated in the 
lung of BALB/c mice, following exposure to allergen. In 
humans, Liao et al. (84) demonstrated that IL-19 levels were 
elevated 3-4-fold in the serum of children with asthma, 
compared to normal children or adults. High IL-19 level 
correlated with IL-4 and IL-13 levels. Huang et al (39) 
expanded these results, demonstrating that IL-4 and IL-13 elicit 
the production of IL-19. On the other hand, it was also shown 
52 
 
that IL-19 is sufficient to induce the production of Th2 
cytokine production in vivo (55).  
On the basis on these considerations, it is not surprising the 
finding of an increase of IL-19 in CRS, given the known link 
between CRS and asthma. The nose and the bronchi belong, in 
anatomical and physiopathological terms, to the concept of 
united airways. Associations between upper and lower airways 
diseases have been demonstrated since allergic rhinitis and 
CRS are all associated to asthma.  
In this context, it could be hypothesized that the increase of IL-
19 in patients with CRS, could be considered as a biomarker of 
subsequent evolution to asthma. This could be in particular for 
those patients, with CRS with NP, showing the highest 
expression of IL-19. Indeed, asthma improves after medical or 
surgical treatment of NPs. A recent study reported that in 
patients with NPs the incidence of asthma was remarkable 
(48,9%) and that skin prick tests were positive in 63,2% of 
these patients.   
The involvement of IL-19 in immune response, as a modifier 
of Th1/Th2 balance in favor of Th2 pathway, suggests a 
possible role in allergic disease. However, we did not found 
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any difference of IL-19 expression between allergic and non-
allergic NPs, ruling out an association of IL-19 with allergy. 
Epithelial damage and aberrant tissue remodeling are common 
features in NP. Features of nasal remodeling may be 
considered: squamos metaplasia, basement membrane 
thickening, collagen deposition, hyperplasia of mucous glands, 
and globet cells (96). Mucus hypersecretion is a common 
pathologic change in chronic inflammatory airway disease 
associated with hyperplasia and metaplasia of secretory cells 
(97). In this regard, persistent mucoid and mucopurulent 
rhinorrhea are some of the major clinical features in CRS and 
CRS/NP. Here, it has been demonstrated that IL-19 is up-
regulated at both mRNA and protein level and its higly 
expressed by the squamous metaplastic epithelium of nasal 
polyps.  
The exact role of IL-19 in goblet cell metaplasia in CRSwNp 
patients is not clear, but on the basis of previously finding, we 
suggested that the presence of IL-19 in metaplastic ephitelium 
may play a role of the upper airways remodeling phenomena in 
certain people who develop polyps, irrespective of whether or 
not they are atopic.  
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Data on a possible role of IL-19 in tissue remodeling in 
asthmatic patients are still lacking. IL-19 was involved in the 
pathogenesis of asthma, through its modulatory role on Th2 
cytokines. In contrast, we showed that in upper airways the role 
of IL-19 more related to tissue remodeling, being associated to 
squamous metaplasia of NP tissue. Considering the close 
relationship between asthma and CRS, it is possible that also in 
asthma IL-19 could play a role in tissue remodeling. On the 
other hand, the lack of correlation with allergy in the present 
study we seems to suggest that possible different mechanisms 
may be activated in upper and lower respiratory tract. Ongoing 
studies are now exploring this complex issue. 
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CONCLUSIONS 
 
The results of the present study provide evidence on a putative 
role of IL-19 in NPs tissue remodeling, in patients with CRS 
independently on their allergic status.    
Given the role of IL-19 in asthma and the tight relationships 
between asthma and CRSwNP, further studies will aim to 
understand a possible role of IL-19 as predictor of subsequent 
development of asthma for patients with CRSwNP.  
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MATERIAL AND METHODS 
 
Subjects group  
Patients were recruited at the ―Dipartimento di 
Otorinolaringoiatria, Palermo, Italy‖ and at the Department of 
Otorhinolaryngology-Ghent, Belgium. A total of 25 patients 
and 15 control subjects were included in this study: group 1, 
control (CON); group 2, CRS patients without NPs 
(CRSw/oNP) (n=10); the last, group 3, nasal polyps from CRS 
patients (CRSwNP) (n=15). The diagnosis of CRS was based 
on history, clinical examination, nasal endoscopy, and CT 
scanning of the sinuses according to the European Position 
Paper on Rhinosinusitis and Nasal Polyps guidelines (Fokkens 
W., Allergy 2005). The patients with Samter‘s syndrome and 
systemic diseas (cystic fibrosis, autoimmune systemic diseases, 
hyper-responsiveness to aspirine) were not included in the 
study. The control group consisted of inferior turbinate 
specimens of patients, without polyp and without rhinosinusitis 
and allergic rhinitis who underwent partial inferior turbinate 
excision and septoplasty.  
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All procedures were performed in accordance with the ethical 
guidelines, and they had approval by the Ethics Committee of   
our Hospital and was in agreement with the Helsinki 
Declaration. All subjects had given their informed consent. 
 
 
Nasal biopsies and tissue handling 
Tissue samples from nasal polyps and tissue samples of the 
normal nasal mucosa from inferior turbinate were performed 
under local anesthesia. Prior to surgery, 2% tetracaine HCl 
were applied topically to the turbinates, nasal septum and 
middle meatus. After decongesting, the polyp was injected with 
2-4 ml of 1% lidocaine with 1:1000000 adrenaline. Then, the 
polyps were removed using gentle traction and snare technique. 
 
Tests for Allergy and Atopy and Determination 
Patients were tested for allergy and atopy by using skin print 
test (SPT) and measuring serum total and specific-IgE levels 
(DPC-Immulite 2000). A panel of common allergens was used 
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for SPT and specific IgE including animal, house dust, grass, 
tree, mold, food, and weed panel allergens. SPTs were 
performed after histamine provocation. After 15 minutes, 
interpretation was done as: 0, negative, erythema only or no 
reaction; 1         3mm; 2+, wheal 3 to 5 mm with flare; 
3+, wheal ≥5 to 7 mm with flare; and 4+, wheal ≥7 mm usually 
with pseudopods and flare. The patient was considered prick 
test positive, if at least 1 allergen elicited a weal diameter was 
at least 3 mm larger than that of the negative control. 
 
 
Evaluation of RNA extraction yeld, purity and integrity 
Total RNA was isolated from the samples using TriZol reagent 
(Invitrogen, California, USA), as described in manufacture‘s 
protocol. RNA quality was evaluated by evaluated by running 
on a 1% agarose gel and inspecting for distinct 18S, 28S, and 
tRNA bands, indicating lack of degradation; quantity was 
determined by spectrophotometry analysis and finally purity of 
each sample was determined by calculating the 260/230 ratios. 
Sample were frozen at -80°C until use. 
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Gene expression Arrays (GEArray Q series Gene Array, 
SuperArray) 
At the time of the surgery, nasal polyps and nasal mucosa of 
each grups, were immediately separated, kept in RNAlater© 
(Ambion, Italy) and place at 4°C until the time of the analysis. 
Total RNAs were isolated from samples, using TRIzol reagent 
(Invitrogen). The levels of RNA purity and degradation were 
assessed spectrophotometrically and evaluated in a 1% agarose 
gel electrophoresis. Total RNA was used as a template for 
biotinylated probe synthesis. cDNA probes were created with a 
standardized validated technique (Super Array, Inc, Bethesda, 
MD). Hybridization studies were conducted with a focused 
gene array technique (Human Pathway Finder or Human 
Asthma gene array (Super Array, Inc). The nylon membranes 
were prehybridized with heat-denatured sheared salmon sperm 
DNA and diluted in GEAhyb Hybridization Solution (Super 
Array, Inc) for 2 hours at 60°C. cDNA probes were then added 
in a hybridization tube filled with GEAhyb hybridization 
solution and were hybridized overnight with continuous 
agitation at 60°C. After blocking with SuperBlock (Pierce, 
<Rockford, IL) (SuperArray) and incubation with alkaline 
phosphatase-conjugated streptavidin (1:5000), the membranes 
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were exposed to CDP-Star chemiolumionescent substrate 
(Tropix, Inc, Bedford,MA) (SuperArray) for 2 minutes. The 
images obtained after film exposure were digitized with Adobe 
Photoshop software according to specications, and analyzed 
with the GEArray Expression Analysis Suite (SuperArray 
Bioscence Corp, Frederick, MD). Expression of housekeeping 
genes such as β-actin and glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH) were used for data normalization. 
The relative expression of each gene in the pretreatment and 
posttreatment groups was determined by comparing the signal 
intensity and results were reported in light intensity units. 
 
Statistical Analysis 
Statistical analysis was performed with the GEArray 
Expression Analysis Suite (SuperArray Bioscience Corp, 
Frederck, MD). Results were considered significant when there 
was at least a 1.5-fold difference between the pretreatment and 
post-treatment sample intensities. Data were further analyzed 
with Microsoft Excel (Microsoft Corp, Redmond, WA) 
statistical software. 
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Real-Time Polymerase Chain Reaction (PCR) 
Total cellular RNA was extracted from nasal biopsies using the 
TRIzol Reagent (Invitrogen, Carlsbad, CA, USA), according to 
the method of Chomezynski an Sacchi (1), and was reverse-
transcribed to cDNA, using ;-MLV-RT and oligo (dT)12-18 
primers (Invitrogen). Real –Time quantitative PCR of IL-19 
transcript was carried out on ABI PRISM 7900 HT Sequence 
Detection Systems (Applied Biosystems, Foster City, CA, 
USA) using specific FAM-labelled probe and primers (Applied 
B yosistems, TaqMan Assay on Demand). GAPDH gene 
expression was used as endogenous control for normalization. 
Relative quantitation of mRNA levels was carried out with 
comparative Ct method (100) and was plotted as fold-change 
compared to the normal sample expressing the least level of 
IL_19 transcript, that was chosen as the reference sample. 
 
Western Blot Analyses of IL-19 
Total proteins from human nasal turbinates and nasal polyps 
were prepared using Paris TM Kit (Ambion) as described in 
manufacturer‘s protocol. Cell extracts were transferred in 
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microcentrifuge tubes, left on ice for 45 min, and centrifuged at 
15,000g for 20 min at 4°C. Fourthy micrograms of proteins 
were subjected to SDS-polyacrylmide, resuspended in 2µl 
Laemmli buffer 10X and separated by SDS-PAGE gel 
electrophoresis at 12% gradient gels and blotted onto 
nitrocellulose membranes. These was blocked overnight at 4°C 
with PBS containing 5% milk and 0,1% Tween 20 (5%milk-
PBST), and then probed  with a polyclonal Ab directed against 
human IL-19 (IL-19(C-20): sc-16729(Santa Cruz) diluited at 
1:100 in 5% milk-PBST for 1 hour. The membrane was 
washed with PBST, and incubated with peroxidase-conjugated 
secondary antibodies (anti-goat, Invitrogen) diluited at 1:2000 
in 5% milk-PBST for 1 hour. Detection was performed with an 
enhanced chemioluminescence system (GE Healthcare, 
Chalfont St. Giles, UK). Approximate molecular masse was 
determinate using calibrated prestained standard (GE 
Healthcare). 
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Gel Image Evaluation 
Gel images were taken with an EPSON GT-6000 scanner and 
then imported to a NIH Image analyses 1.61 program to 
determine band intensity. Data are expressed as arbitrary 
densitometric units corrected against the density of β-actin 
bands. 
 
Tissue processing, morphometry and 
immunohistochemistry 
Fragments of polyps and nasal inferior turbinate specimens 
from each patients were removed surgically, fixed 
immedediately in NBF ( Neutral Buffer Formaline 10%) for 24 
hours, and embebbed in paraffine. The sections were cutted at 
4-5 µm and stained by haematoxylin and eosin for test the 
quality. Before deparaffinization in xylene, tissue section slides 
were baked in oven at 37°C for 24 hours on a vertical rack to 
melt the extra layer of coated paraffins. The sections were 
deparaffinised, rehydrated using the following series of 
washes: two xylen washes, followed by one in 100% ethanol 
rinses, one in 80% ethanol, and 50% ethanol. The last wash 
64 
 
were in tap water and TBS (Tris-Bufferd Saline containing 
Tris-HCl 0,5 M ph7.6 and NaCl 1,5 M.) on a shaker. Antigen 
retrieval was optimized by incubating the specimens in a bath 
at 95°C for 45 minutes. The samples were washed in TBS and 
incubated in 0,5% Albumin from Bovine Serum (BSA, Sigma-
Aldrich) in TBS at room temperature for 20 minutes, before 
incubation overnight at 4°C, with primary antibody: IL-19 (C-
20): sc-16729 (Santa Cruz), diluted at a concentration of 1:50 
in TBS. Omission of the Primary antibody was used as 
negative control. The samples were then incubated in 
biotinylated secondary antibody reacts with alkaline 
phosphatase conjugated streptavidin molecules (Universal 
DakoCytomation LSAB2 System, Alkaline Phosphatase). 
Staining is completed after a 15 minutes of incubation with the 
substrate-chromogen solution. Sections were assessed in a 
random order with no knowledge of the patients clinical details 
on two occasions. 
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